CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)		Total	Preferred Stock	Preferred Stock Series D Convertible Preferred Stock	Preferred Stock Series C Convertible Preferred Stock	Common Stock	Common Stock Series D Convertible Preferred Stock	Common Stock Series C Convertible Preferred Stock	Additional Paid-In Capital	Additional Paid-In Capital Series D Convertible Preferred Stock	Additional Paid-In Capital Series E Convertible Preferred Stock	Additional Paid-In Capital Series C Convertible Preferred Stock	Service Receivable	Accumulated Deficit	Accumulated Deficit Series D Convertible Preferred Stock	Accumulated Deficit Series E Convertible Preferred Stock
Balance, beginning (in shares) at Dec. 31, 2018			60,600			3,831,879
Balance, beginning at Dec. 31, 2018		$ 10,084,192	$ 60			$ 7,742			$ 202,267,605				$ 0	$ (192,191,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		200,067							200,067
Issuance of common stock upon exercise of warrants (in shares)						497,313
Issuance of common stock upon exercise of warrants		3,282,266				$ 50			3,282,216
Issuance of common stock upon vesting of restricted stock units (in shares)						6,362
Issuance of common stock upon vesting of restricted stock units						$ 4			(4)
Preferred stock dividend payable on Series A Convertible Preferred Stock		(6,060)												(6,060)
Release of clinical trial funding commitment		70,487											70,487
Net loss		(3,904,771)												(3,904,771)
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)			200,000			183,334
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment		(40,000)	$ 200			$ 110			1,634,690				(1,675,000)
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance									268,269					(268,269)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)						6,466
Balance, ending (in shares) at Mar. 31, 2019			260,600			4,525,354
Balance, ending at Mar. 31, 2019		9,686,181	$ 260			$ 7,906			207,652,843				(1,604,513)	(196,370,315)
Balance, beginning (in shares) at Dec. 31, 2018			60,600			3,831,879
Balance, beginning at Dec. 31, 2018		10,084,192	$ 60			$ 7,742			202,267,605				0	(192,191,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of warrants (in shares)						156,353
Issuance of common stock upon exercise of warrants		1,564				$ 16			1,548
Net loss		(8,030,074)
Balance, ending (in shares) at Jun. 30, 2019			60,600			5,441,390
Balance, ending at Jun. 30, 2019		8,848,235	$ 60			$ 7,997			210,706,090				(1,364,234)	(200,501,678)
Balance, beginning (in shares) at Mar. 31, 2019			260,600			4,525,354
Balance, beginning at Mar. 31, 2019		9,686,181	$ 260			$ 7,906			207,652,843				(1,604,513)	(196,370,315)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		148,834							148,834
Sale of common stock and warrants (in shares)						(421,917)
Sale of common stock and warrants		(2,902,740)				$ (42)			(2,902,698)
Issuance of common stock upon vesting of restricted stock units (in shares)						4,433
Issuance of common stock upon vesting of restricted stock units						$ 0			0
Preferred stock dividend payable on Series A Convertible Preferred Stock		(6,060)												(6,060)
Release of clinical trial funding commitment		240,279											240,279
Net loss		(4,125,303)												(4,125,303)
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)					(200,000)			333,333
Issuance of common stock upon conversion of Series D Convertible Preferred Stock					$ (200)			$ 33				$ 167
Balance, ending (in shares) at Jun. 30, 2019			60,600			5,441,390
Balance, ending at Jun. 30, 2019		8,848,235	$ 60			$ 7,997			210,706,090				(1,364,234)	(200,501,678)
Balance, beginning (in shares) at Dec. 31, 2019			60,600			8,593,633
Balance, beginning at Dec. 31, 2019		7,311,344	$ 60			$ 8,312			217,172,528				(971,673)	(208,897,883)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		177,309							177,309
Sale of common stock and warrants (in shares)						(800,000)
Sale of common stock and warrants		(1,000,001)				$ (80)			(999,921)
Issuance of common stock upon exercise of warrants (in shares)						1,610,144
Issuance of common stock upon exercise of warrants		1,456,369				$ 161			1,456,208
Issuance of common stock upon vesting of restricted stock units (in shares)						6,810
Issuance of common stock upon vesting of restricted stock units						$ 1			(1)
Preferred stock dividend payable on Series A Convertible Preferred Stock		(6,060)												(6,060)
Release of clinical trial funding commitment		293,017											293,017
Net loss		(4,088,562)												(4,088,562)
Balance, ending (in shares) at Mar. 31, 2020			60,600			11,010,587
Balance, ending at Mar. 31, 2020		6,143,418	$ 60			$ 8,554			219,805,965				(678,656)	(212,992,505)
Balance, beginning (in shares) at Dec. 31, 2019			60,600			8,593,633
Balance, beginning at Dec. 31, 2019		7,311,344	$ 60			$ 8,312			217,172,528				(971,673)	(208,897,883)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(8,213,094)
Balance, ending (in shares) at Jun. 30, 2020			926,424			21,325,076
Balance, ending at Jun. 30, 2020		24,384,039	$ 926			$ 9,585			247,528,273				(2,765,164)	(220,389,581)
Balance, beginning (in shares) at Mar. 31, 2020			60,600			11,010,587
Balance, beginning at Mar. 31, 2020		6,143,418	$ 60			$ 8,554			219,805,965				(678,656)	(212,992,505)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		281,776							281,776
Issuance of common stock upon exercise of warrants (in shares)						3,473,393
Issuance of common stock upon exercise of warrants		4,605,017				$ 347			4,604,670
Issuance of common stock upon vesting of restricted stock units (in shares)						2,250
Issuance of common stock upon vesting of restricted stock units						$ 0			0
Preferred stock dividend payable on Series A Convertible Preferred Stock		(6,060)												(6,060)
Release of clinical trial funding commitment		213,492											213,492
Net loss		(4,124,532)												(4,124,532)
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)			154,670			602,833
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment		(7,500)	$ 15			$ 60			2,292,425				(2,300,000)
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance										$ 601,767	$ 2,664,717				$ (601,767)	$ (2,664,717)
Sale of common stock, preferred stock and warrants (in shares)	[1]		865,824			4,689,313
Sale of common stock, preferred stock and warrants	[1]	(17,278,428)	$ 866			$ 469			17,277,093
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)				(154,670)			1,546,700
Issuance of common stock upon conversion of Series D Convertible Preferred Stock				$ (15)			$ 155			$ (140)
Balance, ending (in shares) at Jun. 30, 2020			926,424			21,325,076
Balance, ending at Jun. 30, 2020		$ 24,384,039	$ 926			$ 9,585			$ 247,528,273				$ (2,765,164)	$ (220,389,581)

[1] Net of expenses of $616,143, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666.